Participants 13 85 4
varicella-zoster virus infection in severely immunocompromised patients.
Participants 140 416 10
In a prospective, randomized trial, we compared intravenous acyclovir and vidarabine in the treatment of varicella-zoster virus infection in severely immunocompromised patients who presented within 72 hours of onset of the infection. Eleven patients were treated in each group
